Zymeworks (NASDAQ: ZYME) insider files to sell 30,424 shares

Rhea-AI Filing Summary

Zymeworks Inc. insider Kenneth Galbraith has filed a Form 144 indicating an intention to sell 30,424 shares of common stock on or about 01/12/2026 through Morgan Stanley Wealth Management Canada on Nasdaq, with an aggregate market value of $704,924.08.

The filing shows that 64,000 shares of common stock were acquired on 01/12/2026 through the vesting of restricted stock units from the issuer, with payment described as vesting of an award.

Over the prior three months, the same seller reported two sales of Zymeworks common stock: 47,528 shares on 12/22/2025 for gross proceeds of $1,284,311.12, and 54,343 shares on 01/05/2026 for gross proceeds of $1,363,840.84.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Wealth Management Canada 140 4th Ave. SW, Suite 2740 Calgary A0 T2P 3N3	30424	704924.08	74836534	01/12/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/12/2026	Vesting of Restricted Stock Units	Issuer			64000	01/12/2026	Vesting of Award

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kenneth Galbraith c/o Zymeworks Inc. 108 Patriot Drive, Suite A Middletown DE 19709	Common Stock	12/22/2025	47528	1284311.12
Kenneth Galbraith c/o Zymeworks Inc. 108 Patriot Drive, Suite A Middletown DE 19709	Common Stock	01/05/2026	54343	1363840.84

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ZYME Form 144 filing disclose?

The Form 144 discloses that Kenneth Galbraith intends to sell 30,424 shares of Zymeworks Inc. common stock, with an aggregate market value of $704,924.08, through Morgan Stanley Wealth Management Canada on Nasdaq.

How many Zymeworks (ZYME) shares are planned to be sold under this Form 144?

The notice covers an intended sale of 30,424 shares of Zymeworks common stock.

What recent Zymeworks (ZYME) insider sales are reported in the last three months?

The filing lists two recent sales by Kenneth Galbraith: 47,528 shares sold on 12/22/2025 for $1,284,311.12 and 54,343 shares sold on 01/05/2026 for $1,363,840.84.

How were the Zymeworks (ZYME) shares being sold acquired?

The securities information states that 64,000 shares of common stock were acquired on 01/12/2026 via vesting of restricted stock units from the issuer, with the nature of payment described as vesting of an award.

What is the approximate sale date and market value for the ZYME shares in this notice?

The approximate date of sale is listed as 01/12/2026, and the aggregate market value of the 30,424 shares to be sold is $704,924.08.

How many Zymeworks (ZYME) shares were outstanding in this Form 144?

The securities table shows that Zymeworks had 74,836,534 shares of common stock outstanding at the time referenced in the notice.

On which exchange will the Zymeworks (ZYME) Form 144 shares be sold?

The shares covered by this Form 144 are indicated to be sold on the Nasdaq stock market.